In a phase Ib clinical trial (NCT03172936) of advanced/metastatic solid tumors or lymphomas, the combination of the STING agonist MIW815 (ADU-S100) and spartalizumab (PDR001), a monoclonal antibody directed against PD-1, significantly reduced patient discomfort and improved patient prognosis (Table 1) (102). Here, STING1 is linked to lymphoma.